Navigation Links
Tackling Atrial Fibrillation and Associated Cardiovascular Risk
Date:11/4/2008

- RecordAF Registry Baseline Data and New Data from the Landmark ATHENA

Study
PARIS, Nov. 4 /PRNewswire/ --

Live Webcast Media Briefing - non-US media only

Wednesday 12 November 2008 - 14.00-15.00am CET

Background:

-- AF is a growing health concern directly responsible for increased

morbidity and mortality

-- There is a need for a global prospective database like RecordAF, which

takes a closer look at disease characteristics and how management of AF

affects cardiovascular (CV) outcomes

-- AF is associated with a high hospitalization burden - 70 percent of AF

management costs are driven by hospitalization costs (Ringborg et al.

Europace 2008; 10:403-11)

-- A further sub-analysis of the ATHENA trial was conducted:

-- to better understand the impact of dronedarone on hospitalization

of AF patients particularly on the number and duration of CV and

non CV hospitalization nights

-- An additional sub-analysis was also conducted to further explore

dronedarone's rhythm and rate controlling properties

-- The ATHENA study is the first AF trial designed to evaluate the effect

of an anti arrhythmic drug (AAD) on morbidity and mortality. It showed

that dronedarone (brand name Multaq(R)), a new AAD undergoing the

registration process, can significantly improve CV outcomes including

reducing the risk of hospitalization and death.

Register on-line in advance of the online event:

1. Go to https://sanofiaventismediabriefing.webex.com/sanofiaventismediabriefing/ons t age/g.php?d=702842657&t=a&EA=nburns%40webex.com&ET=6b1f2c181b8fa5176928ed1c 72 009c4d&ETR=8789fb6f20765cb360e4d0c88cea0f23 (due to the length of this URL, please copy and paste it into your browser)

2. Click "Register"

3. On the registration form, enter your information then click "Submit"

Once the host approves your registration, you will receive a confirmation email containing instructions on how to join the event (event number and password) on the day of the announcement.

Once logged on, you will also be required to connect to a teleconference in order to participate in the live Q&A session with panelists at the end of the event.

Teleconference dial in number (toll-free):

1) To obtain your teleconference number, register first by following the instructions above.

2) Once connected, a pop-up window will appear

3) Select country of affiliation to obtain local dial-in number

4) Dial-in and enter your login details using the provided number within the pop-up window

Please ensure you log on to the event 15 minutes before the start time so as not to miss valuable information.

IMPORTANT NOTICE:

This event is not part of the official Scientific Sessions 2008 as planned by the AHA Committee on Scientific Sessions Programming


'/>"/>
SOURCE Sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
2. Further Analysis From ATHENA Study Showed That Multaq(R) (dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
3. Further Analysis From ATHENA Study Showed That Multaq(R)(Dronedarone) Reduced the Risk of Stroke in Patients With Atrial Fibrillation
4. Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies
5. American Heart Journals Publishes Results From ERATO Trial Showing Dronedarone (Multaq(R)) Improves Ventricular Rate Control in Patients With Permanent Atrial Fibrillation
6. Multaq(R) (dronedarone) Granted FDA Priority Review for Patients with Atrial Fibrillation
7. Studies of an Innovative Catheter Ablation System for Atrial Fibrillation Reveal Excellent Outcomes, Safety Profile and Fast Procedure Times
8. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
9. Circulation Publishes Data Showing KYNAPID(TM) (Vernakalant Hydrochloride) Injection Rapidly Converted Short-Duration Atrial Fibrillation to Sinus Rhythm
10. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
11. Boehringer Ingelheim Announces Enrollment is Complete for the Largest Atrial Fibrillation Outcomes Trial - The RE-LY(TM) Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... , May 6, 2016 Zymo Research Corporation will ... at the American Urological Association,s Annual Meeting, the largest ... and isolates total DNA from a large volume of urine ... the company,s booth #5151 at the San Diego ... Conditioning Buffer ™ (UCB ™ ) that preserves ...
(Date:5/6/2016)... May 6, 2016 ReportsnReports.com ... 2016" to its database. The report provides comprehensive ... of the products at various stages of development. ... pipeline product development. It also provides information about ... trial status, trial start and end dates, and, ...
(Date:5/6/2016)... that we now stock the ( most advanced surgical and microscopic camera ) currently available, ... the consumer market in March 2016. Photo - http://photos.prnewswire.com/prnh/20160505/364465 ... ... ... GP-UH532 camera is the newest iteration of Panasonic,s 1080p HD camera and is part of ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... ... This Mother’s Day kicks off the start of an important week not just ... takes place May 8-May 14. , Throughout the celebration, the U.S. Department of ... their health a top priority. Women everywhere are being encouraged to take steps toward ...
(Date:5/6/2016)... MOOREFIELD, W.V. (PRWEB) , ... May 06, 2016 , ... ... by WestBow Press) shares accounts of dying patients who have allowed those holding vigil ... June E. Kuykendall, RN, BSN, CHPN, hopes to help readers spiritually and practically gain ...
(Date:5/5/2016)... Aliso Viejo, CA (PRWEB) , ... May 05, 2016 , ... ... use in Final Cut Pro X. Drag and drop a TransWipe preset between two ... project. Choose from smooth corner wipes to colored panels with customizable color and orientation ...
(Date:5/5/2016)... ... May 05, 2016 , ... Pivot ... the industry’s gold standard KLAS Performance Report, Epic Consulting 2016 - ... organizations that specialize in consulting services for electronic health record (EHR) solutions from ...
(Date:5/5/2016)... ... May 05, 2016 , ... Textile Exchange is ... (RWS) for public stakeholder review. The stakeholder review is an important opportunity for interested ... goals and delivers value to the wool industry., The RWS is intended to be ...
Breaking Medicine News(10 mins):